Table 4 Responses of second uLMS122 Patient Derived Xenograft to PARPi and standard therapy in vivo
From: Targeting homologous recombination deficiency in uterine leiomyosarcoma
| Â | Test Statistica | P-value |
|---|---|---|
Vehicle vs caelyx 1.5Â mg/kg | 0.015 | 0.9 |
Vehicle vs olaparib 150Â mg/kg (6WKS) | 0.65 | 0.4 |
Vehicle vs cisplatin 4Â mg/kg | 13.37 | 0.0003 |
Vehicle vs olaparib 100 mg/kg + cisplatin 4 mg/kg | 13.26 | 0.0003 |
Cisplatin vs olaparib 100 mg/kg + cisplatin 4 mg/kg | 1.40 | 0.2 |
Vehicle vs AZD5305 10Â mg/kg | 8.01 | 0.005 |
Vehicle vs AZD5305 1Â mg/kg | 6.23 | 0.01 |
Olaparib 100Â mg/kg (4WKS) vs AZD5305 10Â mg/kg | 7.60 | 0.006 |
Olaparib 100Â mg/kg (4WKS) vs AZD5305 1Â mg/kg | 6.12 | 0.01 |